Do SGLT‐2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?

Abstract

Highlights• The beneficial cardiovascular (CV) effects of SGLT-2 inhibitors (SGLT-2i) in patients with heart failure are already known.• Whether SGLT-2i exert similar CV effects in heart failure with reduced or preserved ejection fraction is not known.• This meta-analysis showed SGLT-2i exert similar CV benefits irrespective of the types of heart failure. Future trials will confirm or refute the CV effects of SGLT-2i in patients with heart failure with preserved ejection fraction.

Similarities and differences in cardio-renal outcome trials with SGLT-2 inhibitors: call for pharmacogenomic studies?

“…Similarly, a recent meta-analysis of 6 RCTs (n=15,941) also hinted at a significant reduction in the composite of CV death or HHF in people with both HFrEF (n=12,203; 26% relative risk reduction) and HFpEF (n=3,738; 25% relative risk reduction), without any significant heterogeneity (P Interaction =0.90) (25). Another interesting finding has also emerged from the meta-analysis of 2 RCTs (n=7,844) stratified on glycemic parameter in patients with HFrEF.…”

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction

“…A recent meta-analysis of randomized controlled studies regarding effects of SGLT2i in ∼16,000 patients with HF with or without T2DM, indicated that the subgroup of patients with HFpEF may also achieve a risk reduction of the composite endpoint of cardiovascular death or HF hospitalization (Singh et al, 2021). The SOLOIST-WHF trial investigated the effects of the dual SGLT1 and SGLT2 inhibitor sotagliflozin in 1222 T2DM patients recently hospitalized for worsening of HF.…”